NCT02485015

The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

The Randomized, Controlled, Multicenter Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: The First People's Hospital of Changzhou · Academic / Other
• Sex: Female
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib as the third line therapy for patients with advanced gastric cancer.

Detailed description

400 patients with stage Ⅳ Gastric Cancer,who had received surgery and chemotherapy,will be randomly divided into group A（receive Apatinib and CIK treatment ) or group B（just receive Apatinib),and the randomize ratio will be 1:1. Patients in group A will receive 3 cycles of CIK treatment (every 1 year) and Apatinib (continuous).Patients in group B will receive only Apatinib (continuous) .

Conditions

• Stomach Neoplasms

Interventions

Type	Name	Description
BIOLOGICAL	Cytokine-Induced Killer Cells	Cytokine-Induced Killer Cells are used to treat advanced gastric cancer patients with Apatinib.
DRUG	Apatinib	Advanced gastric cancer patients take Apatinib 850mg qd by mouth.

Timeline

• Start date: 2015-06-01
• Primary completion: 2030-06-01
• Completion: 2033-06-01
• First posted: 2015-06-30
• Last updated: 2016-02-19